title: The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies.
authors.forename: C P
authors.initials: CP
authors.lastname: Engelfriet
authors.forename: H W
authors.initials: HW
authors.lastname: Reesink
authors.forename: P M
authors.initials: PM
authors.lastname: Mannucci
authors.forename: A
authors.initials: A
authors.lastname: Gringeri
authors.forename: J
authors.initials: J
authors.lastname: Ingerslev
authors.forename: D B
authors.initials: DB
authors.lastname: Brettler
authors.forename: E P
authors.initials: EP
authors.lastname: Mauser-Bunschoten
authors.forename: C
authors.initials: C
authors.lastname: Negrier
authors.forename: E
authors.initials: E
authors.lastname: Berntorp
authors.forename: O P
authors.initials: OP
authors.lastname: Smith
authors.forename: A D
authors.initials: AD
authors.lastname: Shapiro
mesh_terms: D000917:Antibody Formation / Q000502:physiology; D001323:Autoantibodies / Q000097:blood / Q000276:immunology; D005164:Factor IX / Q000037:antagonists & inhibitors / Q000276:immunology* / Q000627:therapeutic use; D005169:Factor VIII / Q000037:antagonists & inhibitors / Q000276:immunology* / Q000627:therapeutic use; D006467:Hemophilia A / Q000628:therapy*; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D001323:Autoantibodies; D011994:Recombinant Proteins; D005169:Factor VIII; D005164:Factor IX